The FDA added six therapies to its Commissioner’s National Priority Voucher pilot, expanding the pool of drugs eligible for accelerated review under a program tied to national priorities. The new additions bring the total awarded to 15, and include high‑profile obesity and metabolic agents linked to recent White House engagements with manufacturers. The vouchers are intended to compress review times from the standard 10–12 months to a matter of months for sponsor‑designated applications; the agency framed the move as aligning regulatory resources with public‑health priorities. Industry sees value in priority review for commercial timing; critics warn the program could shift FDA resources and create market distortions if not tightly managed. The expansion also reflects political pressure to accelerate access to certain medicines.